Mixed Specifier

Historically, Kraepelin’s concept of “manic-depressive insanity” viewed mixed states as central, but DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, fourth Edition, Text Revision) narrowly defined them as simultaneous full manic and depressive syndromes. DSM-5 broadened the scope with the “with mixed features” specifier for manic, hypomanic, and depressive episodes, though it excluded overlapping symptoms like irritability and psychomotor agitation. Prevalence varies widely (6–40%) depending on criteria. Clinically, mixed features are linked to early onset, rapid cycling, high comorbidity with anxiety and substance use disorders, poor treatment response, and elevated suicide risk. Neurobiological studies implicate catecholamine dysregulation, inflammatory cytokines, and Hypothalamic–Pituitary–Adrenal axis hyperactivity. In major depressive disorder with mixed features, antidepressants may be combined with mood stabilizers or atypical antipsychotics, while in bipolar mixed depression, antidepressant monotherapy is avoided. Atypical antipsychotics such as lurasidone, cariprazine, olanzapine, and ziprasidone are preferred for their dual antidepressant and antimanic effects, with mood stabilizer combinations and electroconvulsive therapy used for severe or refractory cases. Future research should refine diagnostic criteria, clarify the relationship between mixed depression and the bipolar spectrum, and develop targeted treatments to improve outcomes in this high-risk population.